# Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

> **NCT04430517** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mclean Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Mild Cognitive Impairment
- Mild Alzheimer Disease

## Interventions

- **DRUG:** Nicotinamide riboside

## Key facts

- **NCT ID:** NCT04430517
- **Lead sponsor:** Mclean Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430517, "Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04430517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*